Description
Mirum Pharmaceuticals is a biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of therapies for rare and orphan diseases. The Company's main focus is the development and commercialization of LIVMARLI (maralixibat) oral solution (Livmarli) and Volixibat.
Its pipeline consists of rare pediatric indications for Livmarli and orphan adult indications for its second product candidate, Volixibat. Livmarli is an oral solution as a once-daily medicine for cholestatic pruritus in patients with Alagille syndrome (ALGS) one year of age and older. Volixibat, is an oral, minimally absorbed agent designed to inhibit ileal bile acid transporter (IBAT), for the treatment of adult patients with cholestatic liver diseases.
The Company is developing volixibat for the treatment of intrahepatic cholestasis of pregnancy (ICP), primary sclerosing cholangitis (PSC), and primary biliary cholangitis (PBC).
